Ozempic maker overtook LVMH as Europe's most valuable company
Ozempic's maker was briefly Europe's biggest market cap stock
Novo Nordisk Competes With LVMH to Be Europe's Most Valuable Firm
Ozempic and Wegovy: Novo Nordisk Obesity Drugs Ripple Through
Wegovy Obesity Drug Hit Makes Novo Nordisk More Valuable Than
Novo Nordisk Briefly Overtakes LVMH as Biggest European Company
Ozempic manufacturer Novo Nordisk spent $11 million last year
Novo's Wegovy supply rebound on track for later this year as
Novo Nordisk says ~80% of insured U.S. patients pay less than $25
Clinical Trials Arena
Novo Nordisk sales by quarter 2023